Gibson Christopher 4

What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), converted 40,000 shares of Class B common stock into Class A common stock (no cash consideration) and sold 40,000 shares in the open market on Jan 20, 2026 at $4.47 per share, generating $178,800 in proceeds. The Form 4 shows conversion (transaction code C) and a market sale (transaction code S) the same day — effectively a conversion followed by an immediate sale.

Key Details

• Transaction date: 2026-01-20; Form 4 filed 2026-01-22 (filed within the typical two-business-day window).
• Sale: 40,000 shares at $4.47 each; proceeds $178,800.
• Conversions: two conversion (C) entries for 40,000 shares at $0 — one reflects acquisition of Class A on conversion; the other reflects the derivative disposition related to that conversion.
• Notable footnotes:
  • F1: Class B common is convertible into Class A at the holder’s option (no expiration).
  • F2: The sale was made pursuant to a pre-established Rule 10b5-1 trading plan adopted May 12, 2025.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context

• This was a sale, not a purchase—sales are common for insiders for diversification or liquidity and do not alone indicate company performance.
• The conversion + same-day sale functioned like a cashless exercise/transfer: the director converted Class B into Class A and sold the resulting shares.
• The use of a 10b5-1 plan means the sale was executed under a prearranged trading program, which can reduce insider-timing concerns.